| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The production of hazardous character oxyketone (CPO), which has opposing affinity for the active site of serine inhibitory enzymes (like AChE), is regulated by toxic acid through desulfurization [2]. Characteristics of toxicity (3.9-250 μM; 24-72 h) on serine that inhibits the enzymes' active site (like AChE). The toxicity features (7.5-480 μM; 18 h) cause nuclear condensation, raise the activity of caspase 3/7 (60 μM; 2, 4 h), and increase the number of central stars. The progenitor cells of oligodendrocytes are cytotoxic [3]. H2DCF-DA intensity is increased by cellular heme oxygenase-1 mRNA expression (30, 60, 120 μM; 24 h) [3].
|
|---|---|
| ln Vivo |
The lethal dose (LD< sub>50) for 50% of the sample is 97-276 mg/kg, and the toxicity characteristics are moderate acute injury toxicity and po; singleose[2]. 1 mg/kg and 5 mg/kg as 1 mL/kg; subcutaneous injection; once daily for 3 days) to manage pregnancy tracking on days 9–12 of pregnancy, which could cause adverse effects and abnormal behavior in the offspring [4].
|
| Cell Assay |
Cell Viability Assay [3]
Cell Types: Oligodendrocyte CG-4 Cell Tested Concentrations: 3.9, 7.8, 15.6, 31.25, 62.5, 125 and 250 μM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: More than 62.5 μM Significant Inhibit cell viability. Immunofluorescence [3] Cell Types: Oligodendrocyte CG-4 Cell Tested Concentrations: 0, 30, 60, 120 μM Incubation Duration: 24 hrs (hours) Experimental Results: Nuclear pyknosis and elevation in a dose-dependent manner. |
| References |
[1]. Silva MH. Effects of low-dose chlorpyrifos on neurobehavior and potential mechanisms: A review of studies in rodents, zebrafish, and Caenorhabditis elegans. Birth Defects Res. 2020 Apr 1;112(6):445-479.
[2]. Choi K, et al. Metabolism of chlorpyrifos and chlorpyrifos oxon by human hepatocytes. J Biochem Mol Toxicol. 2006;20(6):279-91. [3]. Saulsbury MD, et al. Chlorpyrifos induces oxidative stress in oligodendrocyte progenitor cells. Toxicology. 2009 May 2;259(1-2):1-9. [4]. Icenogle LM, et al. Behavioral alterations in adolescent and adult rats caused by a brief subtoxic exposure to chlorpyrifos during neurulation. Neurotoxicol Teratol. 2004 Jan-Feb;26(1):95-101. |
| Molecular Formula |
C9H11CL3NO3PS
|
|---|---|
| Molecular Weight |
350.57
|
| Exact Mass |
348.93
|
| CAS # |
2921-88-2
|
| Related CAS # |
Chlorpyrifos-d10;285138-81-0
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CCOP(=S)(OCC)OC1=C(C=C(C(=N1)Cl)Cl)Cl
|
| Synonyms |
Chlorpyrifos Stipend SusconSpannit
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~285.23 mM)
DMSO : ~50 mg/mL (~142.62 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (17.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.13 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8525 mL | 14.2625 mL | 28.5250 mL | |
| 5 mM | 0.5705 mL | 2.8525 mL | 5.7050 mL | |
| 10 mM | 0.2852 mL | 1.4262 mL | 2.8525 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
